|
An Untested Approach: Biomarkers for Colon Cancer
|
1R21CA121294-01A1
|
$119,310
|
MATTA, KHUSHI
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Analysis of Circulating Tumor Cells in a Phase I/II Study for Breast Cancer
|
5R21CA121541-02
|
$307,278
|
SWABY, RAMONA
|
FOX CHASE CANCER CENTER
|
|
Angiogenesis imaging
|
Z01 BC 010714
|
$186,965
|
Choyke, Peter
|
CCR (NCI)
|
|
Anti-Idiotype Therapy of Human B Cell Malignancy
|
5R37CA033399-26
|
$594,988
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
|
Z01 BC 010647
|
$292,262
|
Rader, Christoph
|
CCR (NCI)
|
|
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors
|
2P01CA043904-16A1
|
$2,922,793
|
RAUBITSCHEK, ANDREW
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Atlanta Regional Community Clinical Oncology Program
|
5U10CA045450-21
|
$623,000
|
SEAY, THOMAS
|
ST. JOSEPH'S HOSPITAL
|
|
B7-DC Cross-linking antibody immunotherapy
|
1R21CA130071-01
|
$285,291
|
MARKOVIC, SVETOMIR
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Beaumont Community Clinical Oncology Program
|
5U10CA095860-06
|
$1,030,000
|
DECKER, DAVID
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Bevacizumab and radiation therapy for sarcomas
|
5R21CA117128-02
|
$308,544
|
YOON, SAM
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Biomarkers for VEGF and mTOR Blockade in Advanced Renal Cancer
|
5R21CA119545-02
|
$223,001
|
MERCHAN, JAIME
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
|
5R01CA115755-02
|
$319,025
|
SHARKEY, ROBERT
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Bispecific Antibody Pretargeting for Therapy
|
5R01CA107088-02
|
$477,990
|
SHARKEY, ROBERT
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Bone Marrow Grafting for Leukemia and Lymphoma
|
2P01CA049605-19
|
$3,353,514
|
NEGRIN, ROBERT
|
STANFORD UNIVERSITY
|
|
Busulfan conditioning: optimization, kinetics, genomics
|
5R21CA115097-02
|
$264,975
|
VAN BESIEN, KOEN
|
UNIVERSITY OF CHICAGO
|
|
Cancer Research for the Ozarks
|
3U10CA045560-19S1
|
$120,000
|
GOODWIN, J
|
OZARK HEALTH VENTURE, LLC
|
|
Cancer Research for the Ozarks
|
7U10CA045560-19
|
$546,474
|
GOODWIN, J
|
OZARK HEALTH VENTURE, LLC
|
|
CCOP Research Base, PCPT/PCPT LTFU, and SELECT Programs
|
2U10CA037429-22
|
$14,335,283
|
Coltman, Charles
|
CANCER THERAPY AND RESEARCH CENTER
|
|
CD 74 Directed Immunotherapy for B Cell Malignancies
|
1R21CA126060-01A1
|
$327,262
|
LEONARD, JOHN
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
CD137 Antibody for Cancer Therapy
|
5R01CA106861-05
|
$317,808
|
Chen, Lieping
|
JOHNS HOPKINS UNIVERSITY
|
|
Central Illinois Community Clinical Oncology Program
|
5U10CA045807-22
|
$1,067,633
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-08
|
$3,827,483
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-04
|
$2,163,323
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
3U10CA046368-20S1
|
$32,200
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-20
|
$326,504
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Clinical and Laboratory Studies of Malignant Lymphomas
|
5P01CA034233-23
|
$1,662,201
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
Clinical Development of Hu14.18-IL2 Targeted Therapy
|
5R01CA032685-23
|
$308,597
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
COLUMBIA RIVER ONCOLOGY PROGRAM
|
5U10CA045377-21
|
$776,500
|
LANIER, KEITH
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Columbus Community Clinical Oncology Program
|
3U10CA035261-24S1
|
$120,000
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Columbus Community Clinical Oncology Program
|
5U10CA035261-24
|
$641,747
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Community Clinical Oncology Program
|
3U10CA035431-24S1
|
$120,000
|
DAKHIL, SHAKER
|
VIA CHRISTI REG MED CTR-ST. FRANCIS CMPS
|
|
Community Clinical Oncology Program
|
5U10CA035431-24
|
$1,502,482
|
DAKHIL, SHAKER
|
VIA CHRISTI REG MED CTR-ST. FRANCIS CMPS
|
|
Consortium Therapeutic Studies of Primary Central Nervi*
|
5U01CA105695-04
|
$145,196
|
CLOUGHESY, TIMOTHY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Control of Protein Translation in Cancer Pathogenesis
|
5U01CA084292-09
|
$644,970
|
PANDOLFI, PIER PAOLO
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Dayton Clinical Oncology Program
|
5U10CA035090-25
|
$864,347
|
GROSS, HOWARD
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
|
1R01CA123197-01A1
|
$339,209
|
ZHOU, TONG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Defects in Immunoregulatory Cell Receptors in Patients with Leukemia/Lymphoma
|
Z01 SC 004002
|
$2,581,222
|
Waldmann, Thomas
|
CCR (NCI)
|
|
Development of non-small cell lung cancer tissue microarray for systematic analys
|
Z01 CP 010164
|
$161,956
|
Jen, Jin
|
CCR (NCI)
|
|
Development of Recombinant Toxins for Treatment of Patients with Hematologic Mali
|
Z01 BC 010301
|
$405,903
|
Kreitman, Robert
|
CCR (NCI)
|
|
Development Therapy for Metastatic Colorectal Cancer
|
7R01CA108929-03
|
$253,422
|
HOUGHTON, JANET
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
DF/HCC Renal Cancer SPORE
|
5P50CA101942-05
|
$2,330,598
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL
|
Z01 BC 010648
|
$292,262
|
Rader, Christoph
|
CCR (NCI)
|
|
DNA Methylation & Chromatin Modifications: Mechanisms & Applications in Cancer*
|
5P01CA101956-02
|
$2,215,284
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
3U10CA035269-24S1
|
$80,000
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-24
|
$587,154
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Early prediction of response to combined modality therapy by functional imaging
|
1R21CA123909-01A2
|
$256,372
|
SARKARIA, JANN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Engineered HSV for Treatment of Malignant Gliomas
|
5P01CA071933-10
|
$1,284,905
|
Whitley, Richard
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Enhanced Chemosensitivity of Pancreatic Cancer
|
5R01CA100922-04
|
$258,035
|
WIENTJES, M
|
OHIO STATE UNIVERSITY
|
|
EORTC DATA CENTER
|
5U10CA011488-37
|
$417,479
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|